NEWS & EVENTS

 

Zealand Pharma partner Boehringer Ingelheim initiates Phase 1 trials for diabetes/ obesity treatments

 
Zealand Pharma partner Boehringer Ingelheim initiates Phase 1 trials for diabetes/ obesity treatments

31 August 2017

Zealand Pharma A/S has announced that their strategic collaboration partner, Boehringer Ingelheim, has initiated Phase 1 studies assessing candidates for the treatment of obesity and/or diabetes.

Two compounds invented through the Zealand and Boehringer Ingelheim research collaboration will be trialled: the novel compounds are a dual-acting glucagon/GLP-1 agonist and a long-acting amylin analog

Zealand will receive a EUR 4 million (DKK 30 million) milestone payment related to the initiation of Phase 1 with the long-acting amylin analog.

Results from the trials on both compounds are expected in late 2018.

Read the full press release.

Mewburn Ellis Attorneys Simon Kiddle, Graham ForrestSam Bailey and Sarah Brearley work with Zealand Pharma A/S on their IP portfolio.